A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.
Antimicrob Agents Chemother
; 68(1): e0059823, 2024 Jan 10.
Article
em En
| MEDLINE
| ID: mdl-38047751
ABSTRACT
Shiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adults ex vivo and high neutralizing efficacy in vivo, protecting mice from mortality and HUS-related tissue damage.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Escherichia coli
/
Escherichia coli Shiga Toxigênica
/
Síndrome Hemolítico-Urêmica
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article